Revenue
2018
2019
2020
2021
2022
2023
2024
2025
Vanda Pharmaceuticals Inc. (VNDA)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $216.1M | $198.8M | $192.6M | $254.4M | $268.7M | $248.2M | $227.2M | $193.1M | $165.1M | $146.0M | $109.9M | $50.2M | $33.9M | $32.7M | $31.3M | $35.7M | $4.5M |
| Research & development | $109.3M | $74.4M | $76.8M | $85.8M | $75.4M | $55.6M | $48.6M | $43.6M | $38.5M | $29.2M | $29.1M | $19.2M | $28.5M | $45.8M | $29.0M | $12.3M | $13.9M |
| Operating income | −$151.2M | −$40.7M | −$14.0M | $6.3M | $42.2M | $27.2M | $22.8M | $21.7M | −$16.9M | −$18.6M | −$40.2M | $20.1M | −$21.2M | −$29.2M | −$10.7M | $8.8M | −$35.9M |
| EBITDAderived | −$143.1M | −$32.5M | −$10.9M | $9.1M | $45.0M | $30.1M | $25.7M | $24.7M | −$13.9M | −$6.7M | −$26.6M | $20.6M | −$20.8M | −$28.5M | −$10.2M | $9.2M | −$35.5M |
| Net income | −$220.5M | −$18.9M | $2.5M | $6.3M | $33.2M | $23.3M | $115.6M | $25.2M | −$15.6M | −$18.0M | −$39.9M | $20.2M | −$21.1M | −$28.6M | −$9.8M | $7.2M | −$35.9M |
| Basic EPSper diluted share | -$3.74 | -$0.33 | $0.04 | $0.11 | $0.60 | $0.43 | $2.17 | $0.50 | -$0.35 | -$0.41 | -$0.94 | $0.58 | -$0.69 | -$1.01 | -$0.35 | $0.26 | -$1.33 |
| Diluted EPSper diluted share | -$3.74 | -$0.33 | $0.04 | $0.11 | $0.58 | $0.42 | $2.11 | $0.48 | -$0.35 | -$0.41 | -$0.94 | $0.55 | -$0.69 | -$1.01 | -$0.35 | $0.25 | -$1.33 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Mar 2, 2026Form 4 | Moran Kevin PatrickSVP, CFO & Treasurer | SellCommon Stock | 42.4K | $8.27 | $351.0K | 411.4K |
| Mar 2, 2026Form 4 | Wijkstrom JoakimSVP, Chief Marketing Officer | SellCommon Stock | 30.8K | $8.27 | $254.7K | 333.5K |
| Mar 2, 2026Form 4 | Williams TimothySVP & General Counsel | SellCommon Stock | 42.4K | $8.27 | $350.9K | 377.4K |
| Mar 2, 2026Form 4 | Birznieks GuntherSVP, Business Development | SellCommon Stock | 42.4K | $8.27 | $350.9K | 494.2K |
| Mar 2, 2026Form 4 | Polymeropoulos Mihael HristosPresident and CEO | SellCommon Stock | 156.2K | $8.17 | $1.28M | 2.70M |